Schwarz/Cytel In Cylexin Agreement
Schwarz Pharma and Cytel are to collaborate on the development of the latter's carbohydrate selectin blockers, including Cylexin, which is currently in Phase II testing as a treatment for reperfusion injury after restoration of blood flow following thrombolysis for myocardial infarction.
The two companies will develop an integrated North American and European development plan. Schwarz will have responsibility for marketing the products in Europe, and both companies will share marketing responsibility for North America. Marketing rights in the Far East have been granted to Sumitomo under a 1991 agreement. Cytel retains all manufacturing rights for the compounds.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze